Current and future therapeutic approaches for the treatment of small cell lung cancer

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

(2017) Marcello Tiseo et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)

(2017) Michael J. Seckl et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial

(2017) Lauren Averett Byers et al.   Journal of Thoracic Oncology

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

(2017) Toshiaki Takahashi et al.   LANCET ONCOLOGY

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial

(2017) Ben J. Slotman et al.   LUNG CANCER

Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor

(2017) Kentaro Inamura et al.   Cancer Medicine

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

(2016) Chandra P. Belani et al.   CANCER

A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113

(2016) Rachel E. Sanborn et al.   CANCER

Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer

(2016) Dimitrios T. Trafalis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract 3870: SLFN11 is a biomarker of sensitivity to PARP inhibition and chemotherapy in small cell lung cancer (SCLC)

(2016) C. Allison Stewart et al.   CANCER RESEARCH

No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials

(2016) Giandomenico Roviello et al.   Clinical Lung Cancer

Optimal drugs for second-line treatment of patients with small-cell lung cancer

(2016) Antonio Rossi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

(2016) Koichi Goto et al.   LANCET ONCOLOGY

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

A phase II study of nintedanib in patients with relapsed small cell lung cancer

(2016) Ji-Youn Han et al.   LUNG CANCER

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients

(2016) Nobuyuki Horita et al.   Scientific Reports

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†

(2015) J.-L. Pujol et al.   ANNALS OF ONCOLOGY

Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer

(2015) Oleg Gladkov et al.   ANTI-CANCER DRUGS

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

(2015) Giovenzio Genestreti et al.   Clinical Lung Cancer

PD-L1 expression in small cell lung cancer

(2015) Takefumi Komiya et al.   EUROPEAN JOURNAL OF CANCER

PD-L1 expression in small cell neuroendocrine carcinomas

(2015) Anne M. Schultheis et al.   EUROPEAN JOURNAL OF CANCER

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

(2015) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)

(2015) Neal E. Ready et al.   JOURNAL OF CLINICAL ONCOLOGY

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer

(2015) Hidenobu Ishii et al.   Journal of Thoracic Oncology

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

(2015) Shun Lu et al.   Journal of Thoracic Oncology

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Radiotherapy for extensive stage small-cell lung cancer – Authors' reply

(2015) Ben J Slotman et al.   LANCET

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

(2015) Ben J Slotman et al.   LANCET

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

(2015) Bohuslav Melichar et al.   LANCET ONCOLOGY

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials

(2014) Andrea Ardizzoni et al.   EUROPEAN JOURNAL OF CANCER

Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer

(2014) Neelesh Sharma et al.   INVESTIGATIONAL NEW DRUGS

Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer

(2014) Jeffrey W. Allen et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer

(2014) Philip E. Lammers et al.   Journal of Thoracic Oncology

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

(2014) Marjorie G. Zauderer et al.   LUNG CANCER

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

(2014) Corey J. Langer et al.   LUNG CANCER

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) M. Fruh et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study

(2013) David R. Spigel et al.   Clinical Lung Cancer

Aurora Kinase Inhibition As an Anticancer Strategy

(2013) John F. Hilton et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Duration of Chemotherapy for Small Cell Lung Cancer: A Meta-Analysis

(2013) Hang Zhou et al.   PLoS One

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

(2012) Antonio Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY

A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer

(2012) Taofeek K. Owonikoko et al.   Journal of Thoracic Oncology

Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group

(2012) Giannis Mountzios et al.   LUNG CANCER

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

(2012) Ji-Youn Han et al.   LUNG CANCER

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer

(2011) Zheng-tao Zhou et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

(2011) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Small-cell lung cancer

(2011) Jan P van Meerbeeck et al.   LANCET

Treatment of small-cell lung cancer in elderly patients

(2010) Athanasios G. Pallis et al.   CANCER

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

(2010) Robert Jotte et al.   JOURNAL OF CLINICAL ONCOLOGY

Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group

(2010) Shadia Jalal et al.   Journal of Thoracic Oncology

Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis

(2010) Antonio Rossi et al.   LUNG CANCER

Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer

(2009) Shilpen Patel et al.   CANCER

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

(2009) Siow Ming Lee et al.   JNCI-Journal of the National Cancer Institute

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial

(2009) Cécile Le Péchoux et al.   LANCET ONCOLOGY

Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks

(2008) Bethany C. Woodhouse et al.   DNA REPAIR

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

(2008) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY